News | 2020.04.15
Like many other research teams at the Institut Pasteur, the Bioinformatics and Biostatistics Hub is engaged in fighting against the COVID-19 pandemic by participating in the curation of GISAID data (Global Initiative on Sharing All Influenza Data). The Hub is the service division of the Computational Biology Department, and is composed of 50 experts in biostatistics and bioinformatics.At the end...
Page avancée | 2020.06.17
All SARS-CoV-2 / COVID-19 from the Institut Pasteur
Vidéo | 2020.02.20
COVID-19 : What we have learnt as of 20 February 2020
Article | 2020.06.22
Fiche maladie redirect en Sars-CoV-2 / Covid-19
Article | 2020.07.07
COVID-19 - The Bioinformatics and Biostatistics Hub on the front line
Événement | 2021.10.07
On the occasion of the 15th edition of the Pasteurdon, join the Institut Pasteur, on Thursday, October 7, in partnership with Figaro Partner, for an online program on the major current public health issues: COVID-19, cancers, antibiotic resistance. See you on October 7 on the Pasteurdon website.
News | 2021.10.18
For the opening of the Pasteurdon 2021, scientists from the Institut Pasteur took part in a digital programme looking at some of the major current issues in medical research, "COVID-19, cancers and antibiotic resistance: meeting Institut Pasteur researchers", in partnership with Figaro Partner. Watch online (in French).
News | 2022.07.11
Following the release of the 2021 edition of the Institut Pasteur's Annual Report, here are some of the year's highlights. Twelve eventful months interspersed with highlightsmajor scientific breakthroughs and key events for the institute in all fields including COVID-19, cancer, neuroscience, genetics, vaccinology and antibiotic resistance.
News | 2023.08.23
Although the biological mechanisms behind the short-term effects of COVID-19 are now known, the same is not true for long COVID. Scientists have recently demonstrated that individuals with this syndrome can present different immune responses, either weak or strong. This is a first step in improving treatment for patients with no apparent immunological traces of SARS-CoV-2 infection.
Document de presse | 2020.03.19
Consortium to be led by the Institut Pasteur and will include Themis and the University of Pittsburgh.CEPI to provide initial US$4.9 million for consortium to develop a Covid-19 vaccine candidate based on measles-vector technology.Partnership becomes eighth Covid-19 vaccine development project that CEPI has signed since Jan 23, 2020 OSLO, NORWAY, March 19, 2020 – CEPI, the Coalition for...